Qlaris Bio commences enrolment in glaucoma therapy trial
Qlaris Bio has announced the enrolment of the first patient in the Phase I/II clinical programme of its lead investigational product candidate, QLS-101, for treating individuals with glaucoma.
Infectious Diseases
Quantum Leap concludes icatibant portion of I-SPY COVID Trial
Quantum Leap Healthcare Collaborative (QLHC) has concluded the enrolment in the icatibant arm of the...
Romark’s investigational Covid-19 drug lowers disease progression in trial
Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide...
Oxford University expands Com-COV2 dose-mixing study with Novavax’s Covid-19 vaccine
The University of Oxford has expanded the Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2) study to include the...
SBU students take part in trial to analyse Covid-19 transmission
Stony Brook University (SBU) students, along with 20 universities in the US, are part of the COVID-19 Prevention Network (CoVPN)...
Akston Biosciences doses first patient with next-gen Covid-19 vaccine
Akston Biosciences has dosed the first participant to receive its vaccine candidate, AKS-452, in a Phase I/II trial in the Netherlands. The open-label trial is being managed by TRACER Europe,…
NIH begins trial of antibody for Covid-19 linked respiratory disease
The National Institutes of Health (NIH) has initiated a Phase II clinical trial of an investigational monoclonal antibody IC14 for treating hospitalised Covid-19 patients with respiratory disease and low blood…
Rigel’s fostamatinib meets primary endpoint in Covid-19 clinical trial
Rigel Pharmaceuticals has reported that the Phase II clinical trial of its oral spleen tyrosine kinase (SYK) inhibitor fostamatinib in treating hospitalised Covid-19 patients met the primary endpoint of safety.…
Regeneron’s antibody cocktail helps prevent and treat Covid-19 in Phase III studies
Regeneron Pharmaceuticals has announced a dual win for its single-dose monoclonal antibody cocktail as Phase IIIa/b trials found the injection effective in both preventing Covid-19 infections and halting the disease’s…
AstraZeneca’s Farxiga falls short in Phase III Covid-19 trial
Results from a Phase III clinical trial to see if AstraZeneca’s (AZ’s) diabetes and heart failure drug Farxiga (dapagliflozin) could help treat high-risk patients hospitalised with Covid-19 have shown that…
RedHill to continue Phase II/III trial of Opaganib for Covid-19
RedHill Biopharma is set to continue the global Phase II/III study of orally administered opaganib (Yeliva, ABC294640) in people hospitalised with severe Covid-19 pneumonia. A novel chemical entity, opaganib is…
